产品
编 号：F010813
产品类型
规格
价格
是否有货
结构图
CAS No: 1020748-57-5
产品详情
生物活性：
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL).
体内研究：
Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P < 0.0001).Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model.Animal Model:NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mouse model
Dosage:0.4 mg/kg
Administration:Intravenous injection (i.v.), three doses, every other day.
Result:Survived much longer but died from ALL after 40 d.Reduced BM-infiltration to 4% on day 8.
体外研究：
Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative).The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP.
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL).
体内研究：
Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P < 0.0001).Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model.Animal Model:NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mouse model
Dosage:0.4 mg/kg
Administration:Intravenous injection (i.v.), three doses, every other day.
Result:Survived much longer but died from ALL after 40 d.Reduced BM-infiltration to 4% on day 8.
体外研究：
Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative).The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备